Asia Pacific Biosimilars Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Asia Pacific Biosimilars Market – by Disease Indication

1.3.2 Asia Pacific Biosimilars Market – by Drug class

1.3.3 Asia Pacific Biosimilars Market – by Route of Administration

1.3.4 Asia Pacific Biosimilars Market – by End User

1.3.5 Asia Pacific Biosimilars Market – by Country

2. Asia Pacific Biosimilars Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Biosimilars Market – Market Landscape

4.1 Overview

4.2 Asia Pacific PEST Analysis

4.3 Expert’s Opinion

5. Asia Pacific Biosimilars Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Chronic Diseases

5.1.2 Cost Effectiveness of Biosimilar Drugs

5.1.3 Rising Approvals of Biosimilars

5.2 Market Restraints

5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing

5.3 Market Opportunities

5.3.1 Patent Expiry of Blockbuster Biologics

5.4 Future Trend

5.4.1 Collaborations for Biosimilars and Clinical Trials

5.5 Impact analysis

6. Biosimilars Market – Asia Pacific Analysis

6.1 Asia Pacific Biosimilars Market Revenue Forecast and Analysis

7. Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 – by Disease Indication

7.1 Overview

7.2 Asia Pacific Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

7.3 Cancer

7.3.1 Overview

7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Diabetes

7.4.1 Overview

7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Autoimmune Diseases

7.5.1 Overview

7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.3 Psoriasis:

7.5.3.1 Overview

7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.4 Arthritis:

7.5.4.1 Overview

7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.5 Others:

7.5.5.1 Overview

7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Others Disease Indications

7.6.1 Overview

7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8. Asia Pacific Biosimilars Market Analysis and Forecast to 2028 – by Drug Class

8.1 Overview

8.2 Asia Pacific Biosimilars Market, by Drug class 2021 & 2028 (%)

8.3 Granulocyte colony-stimulating factors

8.3.1 Overview

8.3.2 Granulocyte colony-stimulating factors Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Insulin

8.4.1 Overview

8.4.2 Insulin Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.5 TNF Blockers and Monoclonal Antibodies

8.5.1 Overview

8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration

9.1 Overview

9.2 Asia Pacific Biosimilars Market, by Application 2021 & 2028 (%)

9.3 Intravenous

9.3.1 Overview

9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Subcutaneous

9.4.1 Overview

9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 – by End User

10.1 Overview

10.2 Asia Pacific Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Homecare

10.5.1 Overview

10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.6 Other

10.6.1 Overview

10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11. Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 – Country Analysis

11.1 Overview

11.1.1.1 China: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 China: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3 China: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.1.3.1 China: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.1.4 China: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.1.5 China: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.1.6 China Biosimilars Market, by End User, 2019–2028 (US$ Million)

11.1.1.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.3 Japan: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.2.3.1 Japan: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.2.4 Japan: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.2.5 Japan: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.2.6 Japan: Biosimilars Market, by End User, 2019–2028 (US$ Million)

11.1.1.3 India: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 India: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.3 India: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.3.3.1 India: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.3.4 India: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.3.5 India: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.3.6 India: Biosimilars Market, by End User, 2019–2028 (US$ Million)

11.1.1.4 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.1 Overview

11.1.1.4.2 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.3 South Korea: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.4.3.1 South Korea: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.4.4 South Korea: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.4.5 South Korea: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.4.6 South Korea: Biosimilars Market, by End User, 2019–2028 (US$ Million)

11.1.1.5 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.1 Overview

11.1.1.5.2 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.3 Australia: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.5.3.1 Australia: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.5.4 Australia: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.5.5 Australia: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.5.6 Australia: Biosimilars Market, by End User, 2019–2028 (US$ Million)

11.1.1.6 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.1 Overview

11.1.1.6.2 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.3 Rest of Asia Pacific: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.6.3.1 Rest of Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.6.4 Rest of Asia Pacific: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.6.5 Rest of Asia Pacific: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.6.6 Rest of Asia Pacific: Biosimilars Market, by End User, 2019–2028 (US$ Million)

12. Biosimilars Market – Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Biosimilars Market

12.3 Inorganic Growth Strategies

12.3.1 Overview

12.4 Organic Growth Strategies

12.4.1 Overview

13. Company Profiles

13.1 Amgen Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Celltrion Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Sanofi SA

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Biocon Ltd

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Samsung Bioepis Co Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Eli Lilly and Co

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Sandoz AG

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Teva Pharmaceutical Industries Ltd

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Pfizer Inc

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Dr. Reddy's Laboratories Ltd

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES

Table 1. Comparison Between Different Drug Developments

Table 2. China Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 3. China Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 4. China Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 5. China Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 6. China Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7. Japan Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 8. Japan Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 9. Japan Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 10. Japan Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 11. Japan Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12. India Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 13. India Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 14. India Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 15. India Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 16. India Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17. South Korea Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 18. South Korea Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 19. South Korea Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 20. South Korea Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 21. South Korea Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22. Australia Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 23. Australia Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 24. Australia Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 25. Australia Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 26. Australia Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 27. Rest of Asia Pacific Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 28. Rest of Asia Pacific Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 29. Rest of Asia Pacific Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 30. Rest of Asia Pacific Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 31. Rest of Asia Pacific Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 32. Recent Inorganic Growth Strategies in the Biosimilars Market

Table 33. Recent Organic Growth Strategies in the Biosimilars Market

Table 34. Glossary of Terms

LIST OF FIGURES

Figure 1. Asia Pacific Biosimilars Market Segmentation

Figure 2. Asia Pacific Biosimilars Market, by Country

Figure 3. Asia Pacific Biosimilars Market Overview

Figure 4. Cancer Segment Held Largest Share of Type Segment in Asia Pacific Biosimilars Market

Figure 5. India is Expected to Show Remarkable Growth During Forecast Period

Figure 6. Asia Pacific: PEST Analysis

Figure 7. Experts’ Opinion

Figure 8. Asia Pacific Biosimilars Market Impact Analysis of Drivers and Restraints

Figure 9. Asia Pacific Biosimilars Market – Revenue Forecast and Analysis – 2020–2028

Figure 10. Asia Pacific Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

Figure 11. Cancer: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. Diabetes: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. Autoimmune Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. Psoriasis: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15. Arthritis: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. Others: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. Others Disease Indications: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18. Asia Pacific Biosimilars Market, by Drug class 2021 & 2028 (%)

Figure 19. Granulocyte colony-stimulating factors Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. Insulin Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. Others Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23. Asia Pacific Biosimilars Market, by Application 2021 & 2028 (%)

Figure 24. Intravenous: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Subcutaneous: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Others: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Asia Pacific Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. Homecare: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31. Other: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32. Asia Pacific: Biosimilars Market, by Key Country – Revenue (2021) (US$ Million)

Figure 33. Asia Pacific: Biosimilars Market, by Country, 2021 & 2028 (%)

Figure 34. China: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35. Japan: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36. India: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37. South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38. Australia: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39. Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Growth Strategies in the Biosimilars Market